Carteolol (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412407

CAS#: 51781-06-7 (free base)

Description: Carteolol (free base) is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.


Chemical Structure

img
Carteolol (free base)
CAS# 51781-06-7 (free base)

Theoretical Analysis

MedKoo Cat#: 412407
Name: Carteolol (free base)
CAS#: 51781-06-7 (free base)
Chemical Formula: C16H24N2O3
Exact Mass: 292.1787
Molecular Weight: 292.38
Elemental Analysis: C, 65.73; H, 8.27; N, 9.58; O, 16.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 51781-21-6 (HCl)   51781-06-7 (free base)  

Synonym: Carteolol (free base), UNII-8NF31401XG, Carteololum

IUPAC/Chemical Name: 2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-

InChi Key: LWAFSWPYPHEXKX-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)

SMILES Code: O=C1NC2=C(C(OCC(O)CNC(C)(C)C)=CC=C2)CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 292.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Carteolol. 2020 Oct 19. PMID: 30000575.

2: Fuwa M, Shimazaki A, Mieda M, Yamashita N, Akaishi T, Taniguchi T, Kato M. Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol. Sci Rep. 2019 May 16;9(1):7491. doi: 10.1038/s41598-019-44028-2. PMID: 31097790; PMCID: PMC6522485.

3: Matsuo M, Kuse Y, Takahashi K, Kuwahara K, Tanito M, Kaidzu S, Shimazawa M, Hara H, Ohira A. Carteolol hydrochloride reduces visible light-induced retinal damage in vivo and BSO/glutamate-induced oxidative stress in vitro. J Pharmacol Sci. 2019 Feb;139(2):84-90. doi: 10.1016/j.jphs.2018.11.010. Epub 2018 Dec 6. PMID: 30580970.

4: Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging. 2007;24(6):509-28. doi: 10.2165/00002512-200724060-00007. PMID: 17571916.

5: Nagai N, Yamaoka S, Fukuoka Y, Ishii M, Otake H, Kanai K, Okamoto N, Shimomura Y. Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles. Int J Mol Sci. 2018 Jan 17;19(1):282. doi: 10.3390/ijms19010282. PMID: 29342127; PMCID: PMC5796228.

6: Soares RR, Razeghinejad MR. Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2018 Oct;19(15):1731-1738. doi: 10.1080/14656566.2018.1518432. Epub 2018 Oct 8. PMID: 30295543.

7: Drugs for common eye disorders. Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-194. PMID: 31770361.

8: Kaji Y, Kiuchi T, Oshika T. Carteolol hydrochloride suppresses the generation of reactive oxygen species and rescues cell death after ultraviolet irradiation of cultured lens epithelial cells. Open Ophthalmol J. 2010 Oct 12;4:60-5. doi: 10.2174/1874364101004010060. PMID: 21283534; PMCID: PMC3031156.

9: Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. PMID: 26526633; PMCID: PMC4695285.

10: Higashiyama M, Tajika T, Inada K, Ohtori A. Improvement of the ocular bioavailability of carteolol by ion pair. J Ocul Pharmacol Ther. 2006 Oct;22(5):333-9. doi: 10.1089/jop.2006.22.333. PMID: 17076627.